Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.

Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications. 

Register Now

Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.

Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.

Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

CAP TODAY

Q-linea nabs second contract in U.S. for ASTar instrument

March 2025—Q-linea announced that it has signed a second commercial contract for its ASTar instrumentation in the United States. Installation and training in a multihospital system will take place by the end of the first quarter this year. The quantitative antimicrobial susceptibility test system uses high-speed, time-lapse microscopy imaging of organisms in positive blood culture samples to determine the minimum inhibitory concentration of specific antimicrobial-organism combinations.

FDA clears Thermo Fisher SARS-CoV-2, flu A/B, RSV test

March 2025—Thermo Fisher Scientific has received FDA 510(k) clearance for the Applied Biosystems TaqPath COVID-19, Flu A, Flu B, RSV Select Panel. The real-time PCR-based multiplex test covers the detection and differentiation of SARS-CoV-2, influenza A and B, and respiratory syncytial virus and enables the detection of co-infection. The panel runs on the Applied Biosystems QuantStudio 5 Dx real-time PCR system.

Labcorp test for advanced solid tumors now for clinical use

March 2025—Labcorp announced that its Labcorp Plasma Complete is now available for clinical use. The assay is a ctDNA-based comprehensive genomic profiling solution for patients with advanced solid tumors. It detects genomic alterations in circulating tumor DNA across 521 genes and covers established and emerging biomarkers associated with FDA-approved therapies, guideline-driven treatments, and clinical trial eligibility.

Roche unveils sequencing by expansion technology

March 2025—Roche unveiled a proprietary sequencing by expansion (SBX) technology that offers ultra-rapid, high-throughput sequencing that is flexible and scalable for a broad range of applications, including whole genome sequencing, whole exome sequencing, and RNA sequencing. The novel sequencing approach uses a sophisticated biochemical process to encode the sequence of a target nucleic acid molecule (DNA or RNA) into a measurable surrogate polymer called an Xpandomer.

FDA clears Roche Elecsys sFlt-1/PlGF ratio for preeclampsia

March 2025—Roche announced that its Elecsys sFlt-1/PlGF ratio for preeclampsia has received FDA 510(k) clearance. The preeclampsia ratio supports the management of pregnant patients who have a singleton pregnancy and is intended to help clinicians stratify hospitalized patients into low- and high-risk categories for developing severe preeclampsia within two weeks of presentation.

MARKETPLACE

TRENDING